657
Views
32
CrossRef citations to date
0
Altmetric
Letter to the Editor

Acute Thyroiditis and Bilateral Optic Neuritis following SARS-CoV-2 Vaccination with CoronaVac: A Case Report

, MD, , MD, , MD, , MD, , MDORCID Icon, , MD, , MD, PhDORCID Icon & , MD show all
Pages 1200-1206 | Received 22 Apr 2021, Accepted 22 Jul 2021, Published online: 17 Aug 2021

References

  • Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020;369(6502):413–422. doi:https://doi.org/10.1126/science.abc0035.
  • WHO. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid19-candidate-vaccines (accessed Jan 15, 2021). 2021.
  • Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines (Basel). 2020;8:3.
  • Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192.
  • Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438.
  • Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488.
  • Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):P803–812.
  • Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med. 2018;50:110–120.
  • Nakayama T. Causal relationship between immunological responses and adverse reactions following vaccination. Vaccine. 2019;37:366–371.
  • Di Pasquale A, Preiss S, Tavares da Silva F, Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015;3(2):320–343. doi:https://doi.org/10.3390/vaccines3020320.
  • Salemi S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010;29(3):247–269. doi:https://doi.org/10.3109/08830181003746304.
  • Raveche ES, Schutzer SE, Fernandes H, et al. Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis. J Clin Microbiol. 2005;43(2):850–856. doi:https://doi.org/10.1128/JCM.43.2.850-856.2005.
  • Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet. 1991;338(8776):1174–1175. doi:https://doi.org/10.1016/0140-6736(91)92034-Y.
  • Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alpérovitch A. [The first episode of central nervous system demyelinization and hepatitis B virus vaccination]. Rev Neurol (Paris). 2000;156:242–246.
  • Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):1174–1175. doi:https://doi.org/10.1016/S1474-4422(08)70215-1.
  • Nachamkin I, Shadomy SV, Moran AP, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 2008;198(2):226–233. doi:https://doi.org/10.1086/589624.
  • Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun. 2001;16(3):309–318. doi:https://doi.org/10.1006/jaut.2000.0491.
  • Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876–3886.
  • Global Advisory Committee on Vaccine Safety. Causality assessment of adverse events following immunization. Wkly Epidemiol Rec. 2001;76(12):85–89.
  • Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;362:1659–1666.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
  • Pau D, Al Zubidi N, Yalamanchili S, Plant GT, Lee AG. Optic neuritis. Eye (Lond). 2011;25:833–842.
  • Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology. 1995;45:244–250.
  • Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand. 1983;68:371–377.
  • Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch Ophthalmol. 1972;87:135–139.
  • Yen MY, Liu JH. Bilateral optic neuritis following bacille Calmette-Guérin (BCG) vaccination. J Clin Neuroophthalmol. 1991;11:246–249.
  • Hegde V, Dean F. Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr. 2005;94:635–636.
  • Topaloglu H, Berker M, Kansu T, Saatci U, Renda Y. Optic neuritis and myelitis after booster tetanus toxoid vaccination. Lancet. 1992;339:178–179.
  • Kitazawa Y, Warabi Y, Bandoh M, Takahashi T, Matsubara S. Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent pneumococcal polysaccharide vaccination. Intern Med. 2012;51:103–107.
  • Laria C, Alió J, Rodríguez JL, Sánchez J, Galal A. Optic neuritis after meningococcal vaccination. Arch Soc Esp Oftalmol. 2006;81:479–482.
  • Kerrison JB, Lounsbury D, Thirkill CE, Lane RG, Schatz MP, Engler RM. Optic neuritis after anthrax vaccination. Ophthalmology. 2002;109:99–104.
  • Payne DC, Rose CE, Kerrison J, Aranas A, Duderstadt S, McNeil MM. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. Arch Neurol. 2006;63:871–875.
  • Han SB, Hwang JM, Kim JS, Yang HK. Optic neuritis following Varicella zoster vaccination: report of two cases. Vaccine. 2014;32:4881–4884.
  • O’Brien P, Wong RW. Optic neuritis following diphtheria, tetanus, pertussis, and inactivated poliovirus combined vaccination: a case report. J Med Case Rep. 2018;12:356.
  • Riikonen R. The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children. Acta Neurol Scand. 1989;80:425–431.
  • Roussat B, Gohier P, Doummar D, et al. [Acute optic neuritis in children: clinical features and treatment. A study of 28 eyes in 20 children]. J Fr Ophtalmol. 2001;24(1):36–44.
  • DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60(4):504–509.
  • Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38:295–301.
  • Shaw FE, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol. 1988;127(2):337–352.
  • Stübgen JP. A literature review on optic neuritis following vaccination against virus infections. Autoimmun Rev. 2013;12:990–997.
  • Cunningham ET, Moorthy RS, Fraunfelder FW, Zierhut M. Vaccine-associated uveitis. Ocul Immunol Inflamm. 2019;27:517–520.
  • Benage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. 2016;113:48–52.
  • Cunningham ET, Moorthy RS. Vaccine-associated posterior uveitis. Retina. 2020;40:595–598.
  • Kumar N, Graven K, Joseph NI, et al. Postvaccination anti-myelin oligodendrocyte glycoprotein neuromyelitis optica spectrum disorder: a case report and literature review of postvaccination demyelination. Int J MS Care. 2020;22(2):85–90.
  • Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25:1907–1914.
  • Duignan S, Wright S, Rossor T, et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol. 2018;60(9):958–962.
  • Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J Neuroophthalmol. 2020;40:398–402.
  • Altay FA, Güz G, Altay M. Subacute thyroiditis following seasonal influenza vaccination. Hum Vaccin Immunother. 2016;12:1033–1034.
  • Girgis CM, Russo RR, Benson K. Subacute thyroiditis following the H1N1 vaccine. J Endocrinol Invest. 2010;33:506.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.